Establishment and Evaluation of Human iPS Cell‐Derived Myeloid Cell Lines Susceptible to SARS‐CoV‐2

Takayuki Hishiki(National Institute of Infectious Diseases), Kazuo Miyazaki(MiCell Technologies (United States)), Naomi Tanga, Ami Murakami, Riéko Suzuki(Shizuoka Red Cross Hospital), Jun Shimizu(MiCell Technologies (United States)), Tomohiko Takasaki(Kanagawa Prefectural Institute of Public Health), Yuka Yoshimura, Koichi Watashi(National Institute of Infectious Diseases), Yua Saito
Microbiology and Immunology
March 10, 2026
Cited by 0


Related Papers